Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Ildong COL-144 (Lasmiditan) in Healthy Korean Volunteers
NCT03937648Phase 1Unknown
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Aug 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (5 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoints: Maximum Serum Concentration at 72 hours, Area Under the Curve to Last Measurable Concentration at 72 hours and 2 more. Status: unknown.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03937648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937648.